Toward 'universal' vaccine: Scientists describe antibodies that protect against large variety of flu viruses

August 9, 2012
A team led by scientists at the Scripps Research Institute and Crucell Vaccine Institute has described three human antibodies that provide broad protection against influenza B virus strains. The work was published in Science Express, the advance online issue of the journal Science, on Aug. 9, 2012. Image courtesy of the Wilson lab, the Scripps Research Institute

A team led by scientists at The Scripps Research Institute and Crucell Vaccine Institute in the Netherlands describes three human antibodies that provide broad protection against Influenza B virus strains. The same team had previously reported finding broadly neutralizing antibodies against Influenza A strains.

The of the new broadly neutralizing , which was reported the journal Science's advance online edition, , on August 9, paves the way for researchers to develop a universal antibody-based therapy for use in severe infections or to protect during an . Importantly, these antibodies may provide key clues to the design of an active universal —designed to protect long-term against flu viruses, not just against the current season's strains.

"To develop a truly universal flu vaccine or therapy, one needs to be able to provide protection against A and influenza B viruses, and with this report we now have broadly against both," said Ian A. Wilson, the Hansen Professor of Structural Biology at Scripps Research, who was senior investigator for the new study with Crucell's Jaap Goudsmit and Robert Friesen.

One of the newly discovered antibodies will be of special interest to flu researchers, because it appears to protect against essentially all influenza B and influenza A strains. "It's the only one in the world that we know of that has been found to do this," said Wilson.

Looking for the Missing Pieces

Influenza B viruses are considered less dangerous than Influenza A viruses, and have been less intensively studied because they have less capacity to mutate into deadly pandemic strains. However, influenza B viruses account for a significant part of the annual flu illness burden in humans.

To find broadly protective antibodies against Influenza B, the team at Crucell generated a large collection of flu antibodies from the immune cells of volunteers who had been given a seasonal flu vaccine. The researchers then screened this collection for antibodies that could bind to a wide variety of influenza B strains.

Three of the antibodies they found in this manner—CR8033, CR8071, and CR9114—protected mice against normally lethal doses of the two major influenza B strains. CR9114 also protected mice against influenza A viruses, including the H1N1 subtype that killed about 17,000 people in a 2009 pandemic. The fact that these antibodies protected against a variety of flu strains suggested they mark functionally important sites, or "epitopes," on the virus that are relatively unchanging (conserved) from one flu strain to the next.

Wilson's team at Scripps Research characterized the newly discovered antibodies' binding sites on influenza viruses using electron microscopy and X-ray crystallography techniques. They found that CR8033 binds to a highly conserved epitope—a functionally important site—on the "head" of the hemagglutinin protein, a structure that studs the outer coat of flu viruses and allows the viruses to stick to vulnerable cells. CR8071 binds to the base of the hemagglutinin head. Most antibodies that bind to the hemagglutinin head and neutralize influenza do so by blocking the virus's attachment to host cells.

"The unique thing about these two antibodies is that they neutralize chiefly by preventing virus particles from exiting infected cells," said Nick Laursen, a research associate in Wilson's laboratory who was a lead author of the study.

A Weak Point on the Virus

Antibody CR9114 turned out to bind to a site on the hemagglutinin stem. "It prevents the hemagglutinin protein from undergoing the shape-change needed for the virus to fuse to the outer membrane of a host cell," said Cyrille Dreyfus, a Wilson lab research associate who also was a lead author of the study. "This appears to be a real weak point of the virus, because this epitope is highly conserved among influenza A subtypes as well as influenza B."

Wilson notes that in a study published in 2009 his laboratory determined the structure of another Crucell antibody that broadly neutralizes influenza A viruses by binding to essentially the same site on the hemagglutinin stem—but in a subtly different way, so that it fails to get a grip on influenza B viruses, too. "With some tweaking of that antibody's binding domains, we might have been able to get a broader effect like CR9114's," Wilson said.

The viral epitope to which CR9114 binds will now be studied extensively by researchers as a target for vaccines and therapies, because it is the only one found so far that is broadly vulnerable to neutralization on both influenza A and B viruses.

Remarkably, CR9114 performed poorly against influenza B in initial lab-dish tests known as microneutralization assays, which test the ability of an antibody to protect cells from viral infection. Yet CR9114 was clearly effective under more realistic conditions in mice, even at low doses. Because it attacks the stem rather than the head of flu virus hemagglutinins, CR9114 also failed to show effects in a widely used test known as the hemagglutinin-inhibition assay.

"As we move towards design of a universal flu vaccine, we need to find more inclusive assays to screen for antibodies such as CR9114, which may be highly effective but have novel mechanisms for neutralization that cannot be detected by the current methods used in influenza vaccine development," Goudsmit said.

Explore further: H1N1 discovery paves way for universal flu vaccine: research

More information: "Highly conserved protective epitopes on Influenza B viruses," Science, 2012.

Related Stories

H1N1 discovery paves way for universal flu vaccine: research

May 8, 2012
University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.

Universal flu vaccine a step closer thanks to discovery of natural antibody

July 7, 2011
Annually changing flu vaccines with their hit-and-miss effectiveness may soon give way to a single, near-universal flu vaccine, according to a new report from scientists at The Scripps Research Institute and the Dutch biopharmaceutical ...

Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strains

May 21, 2012
The pandemic 2009 H1N1 vaccine can generate antibodies in vaccinated individuals not only against the H1N1 virus, but also against other influenza virus strains including H5N1 and H3N2. This discovery adds an important new ...

Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A viruses

July 28, 2011
A paper published today in the scientific research journal Science, describes a novel, proprietary monoclonal antibody (FI6) discovered in a collaboration between Humabs BioMed SA, the Institute for Research in Biomedicine ...

Recommended for you

How defeating THOR could bring a hammer down on cancer

December 14, 2017
It turns out Thor, the Norse god of thunder and the Marvel superhero, has special powers when it comes to cancer too.

Researchers track muscle stem cell dynamics in response to injury and aging

December 14, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) describes the biology behind why muscle stem cells respond differently to aging or injury. The findings, published in Cell Stem Cell, ...

'Human chronobiome' study informs timing of drug delivery, precision medicine approaches

December 13, 2017
Symptoms and efficacy of medications—and indeed, many aspects of the human body itself—vary by time of day. Physicians tell patients to take their statins at bedtime because the related liver enzymes are more active during ...

Estrogen discovery could shed new light on fertility problems

December 12, 2017
Estrogen produced in the brain is necessary for ovulation in monkeys, according to researchers at the University of Wisconsin-Madison who have upended the traditional understanding of the hormonal cascade that leads to release ...

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

3-D printed microfibers could provide structure for artificially grown body parts

December 12, 2017
Much as a frame provides structural support for a house and the chassis provides strength and shape for a car, a team of Penn State engineers believe they have a way to create the structural framework for growing living tissue ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.